Posted by Michael Wonder on 20 Apr 2019
NICE final guidance published for Cimzia
18 April 2019 - NICE has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol).
The guidance is for the treatment of severe plaque psoriasis in adults who have failed to respond to, or are unsuitable for, other systemic therapies.
The guidance is great news for the 1.5 million people in England who have psoriasis, as it can impact all areas of the patients’ life, mentally and physically due to its visible nature. Despite drug development advances in the past decade, patient survey data suggests that moderate to severe psoriasis continues to be under-treated, meaning that Cimzia will help fill an unmet need.
